Plus Therapeutics (NASDAQ:CNSY) Stock Rating Cut to Strong Sell at Zacks Research

Plus Therapeutics (NASDAQ:CNSY) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Wednesday, Zacks reports.

Separately, Weiss Ratings initiated coverage on Plus Therapeutics in a research note on Tuesday, August 4th. They issued a “sell (e+)” rating for the company. Two investment analysts have rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Plus Therapeutics Price Performance

Plus Therapeutics stock opened at $1.88 on Wednesday. Plus Therapeutics has a fifty-two week low of $1.49 and a fifty-two week high of $18.89. The firm has a 50 day moving average of $2.50.

Plus Therapeutics (NASDAQ:CNSY) last announced its earnings results on Friday, August 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.35). Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. The firm had revenue of $0.41 million during the quarter. On average, sell-side analysts expect that Plus Therapeutics will post -4.40 EPS for the current year.

About Plus Therapeutics

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s lead investigational product is RNL, also known as rhenium-186 nanoliposome, an experimental treatment designed to deliver radiation directly to tumors while limiting exposure to surrounding healthy tissue.

Plus Therapeutics is primarily evaluating RNL in cancers of the central nervous system, including recurrent glioblastoma and leptomeningeal metastases.